TD Asset Management Inc Invests $4.62 Million in Revvity, Inc. (NYSE:RVTY)

TD Asset Management Inc acquired a new stake in shares of Revvity, Inc. (NYSE:RVTYFree Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 42,218 shares of the company’s stock, valued at approximately $4,615,000.

Several other institutional investors also recently bought and sold shares of RVTY. Parkside Financial Bank & Trust bought a new position in Revvity in the fourth quarter worth about $25,000. Gladius Capital Management LP raised its stake in shares of Revvity by 84.1% during the 3rd quarter. Gladius Capital Management LP now owns 232 shares of the company’s stock worth $26,000 after acquiring an additional 106 shares in the last quarter. CENTRAL TRUST Co purchased a new stake in Revvity during the fourth quarter valued at approximately $27,000. Benjamin F. Edwards & Company Inc. purchased a new stake in Revvity during the fourth quarter valued at approximately $27,000. Finally, ORG Partners LLC acquired a new stake in Revvity in the fourth quarter valued at approximately $32,000. 86.65% of the stock is owned by hedge funds and other institutional investors.

Revvity Price Performance

Shares of NYSE:RVTY opened at $109.86 on Thursday. Revvity, Inc. has a twelve month low of $79.50 and a twelve month high of $131.96. The company has a current ratio of 2.23, a quick ratio of 1.92 and a debt-to-equity ratio of 0.40. The company has a market cap of $13.56 billion, a PE ratio of 90.79, a price-to-earnings-growth ratio of 2.83 and a beta of 1.08. The company’s 50 day moving average is $105.67 and its 200 day moving average is $104.13.

Revvity (NYSE:RVTYGet Free Report) last released its quarterly earnings data on Monday, April 29th. The company reported $0.98 EPS for the quarter, beating the consensus estimate of $0.94 by $0.04. Revvity had a net margin of 5.49% and a return on equity of 7.37%. The business had revenue of $649.90 million for the quarter, compared to the consensus estimate of $646.83 million. During the same period in the prior year, the firm earned $1.01 EPS. The business’s revenue for the quarter was down 3.7% on a year-over-year basis. On average, sell-side analysts forecast that Revvity, Inc. will post 4.66 EPS for the current year.

Revvity Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, August 9th. Shareholders of record on Friday, July 19th will be paid a dividend of $0.07 per share. The ex-dividend date is Friday, July 19th. This represents a $0.28 dividend on an annualized basis and a dividend yield of 0.25%. Revvity’s payout ratio is currently 23.14%.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on RVTY shares. TD Cowen upped their price target on Revvity from $123.00 to $130.00 and gave the stock a “buy” rating in a research report on Tuesday, April 30th. Robert W. Baird upped their target price on Revvity from $126.00 to $127.00 and gave the company an “outperform” rating in a research report on Tuesday, April 30th. Finally, Jefferies Financial Group started coverage on Revvity in a report on Monday. They issued a “hold” rating and a $115.00 price target for the company. Seven research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from, the company presently has an average rating of “Moderate Buy” and an average price target of $117.92.

Check Out Our Latest Research Report on Revvity

Revvity Profile

(Free Report)

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.

Featured Stories

Want to see what other hedge funds are holding RVTY? Visit to get the latest 13F filings and insider trades for Revvity, Inc. (NYSE:RVTYFree Report).

Institutional Ownership by Quarter for Revvity (NYSE:RVTY)

Receive News & Ratings for Revvity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revvity and related companies with's FREE daily email newsletter.